ACOG Committee Opinion No. 566: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination
- PMID: 23812487
- DOI: 10.1097/01.AOG.0000431054.33593.e3
ACOG Committee Opinion No. 566: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination
Abstract
In the face of dramatic and persistent increases in pertussis disease in the United States, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its guidelines for the use of the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) for pregnant women. The new guidance was issued based on an imperative to minimize the significant burden of pertussis disease in vulnerable newborns, the reassuring safety data on the use of Tdap in adults, and the evolving immunogenicity data that demonstrate considerable waning of immunity after immunization. The revised Advisory Committee on Immunization Practices guidelines recommend that health care personnel administer a dose of Tdap during each pregnancy, irrespective of the patient's prior history of receiving Tdap. To maximize the maternal antibody response and passive antibody transfer and levels in the newborn, optimal timing for Tdap administration is between 27 weeks and 36 weeks of gestation, although Tdap may be given at any time during pregnancy. However, there may be compelling reasons to vaccinate earlier in pregnancy. There is no evidence of adverse fetal effects from vaccinating pregnant women with an inactivated virus or bacterial vaccines or toxoids, and a growing body of robust data demonstrates safety of such use. For women who previously have not received Tdap, if Tdap was not administered during pregnancy it should be administered immediately postpartum to the mother in order to reduce the risk of transmission to the newborn. Additionally, other family members and planned direct caregivers also should receive Tdap as previously recommended (sustained efforts at cocooning). Given the rapid evolution of data surrounding this topic, immunization guidelines are likely to change over time and the American College of Obstetricians and Gynecologists will continue to issue updates accordingly.
Similar articles
-
Committee Opinion No. 718 Summary: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination.Obstet Gynecol. 2017 Sep;130(3):668-669. doi: 10.1097/AOG.0000000000002293. Obstet Gynecol. 2017. PMID: 28832480
-
Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination.Obstet Gynecol. 2017 Sep;130(3):e153-e157. doi: 10.1097/AOG.0000000000002301. Obstet Gynecol. 2017. PMID: 28832489
-
Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.MMWR Recomm Rep. 2006 Dec 15;55(RR-17):1-37. MMWR Recomm Rep. 2006. PMID: 17167397
-
Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2008 May 30;57(RR-4):1-51. MMWR Recomm Rep. 2008. PMID: 18509304 Review.
-
Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.Vaccine. 2012 Jul 27;30(35):5179-90. doi: 10.1016/j.vaccine.2012.06.005. Epub 2012 Jun 15. Vaccine. 2012. PMID: 22709953 Review.
Cited by
-
Perinatal management of fetal supraventricular tachycardia complicated by maternal pertussis.BMJ Case Rep. 2015 Jul 7;2015:bcr2015209909. doi: 10.1136/bcr-2015-209909. BMJ Case Rep. 2015. PMID: 26153285 Free PMC article.
-
Safety and use of tetanus-diphtheria-acellular pertussis-5 (Tdap5) vaccine during pregnancy: findings from 11 years of reporting to a pregnancy registry.Hum Vaccin Immunother. 2021 Dec 2;17(12):5325-5333. doi: 10.1080/21645515.2021.1915038. Epub 2021 Dec 29. Hum Vaccin Immunother. 2021. PMID: 34965196 Free PMC article.
-
Development of improved pertussis vaccine.Hum Vaccin Immunother. 2014;10(8):2450-3. doi: 10.4161/hv.29253. Hum Vaccin Immunother. 2014. PMID: 25424954 Free PMC article. Review.
-
Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response.Vaccine. 2021 Jan 3;39(1):85-120. doi: 10.1016/j.vaccine.2019.01.011. Epub 2019 May 3. Vaccine. 2021. PMID: 31060949 Free PMC article. Review.
-
Maternal Care Providers' Barriers Regarding Influenza and Pertussis Vaccination During Pregnancy in Catalonia, Spain.Matern Child Health J. 2018 Jul;22(7):1016-1024. doi: 10.1007/s10995-018-2481-6. Matern Child Health J. 2018. PMID: 29417364
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical